These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19185986)

  • 1. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
    Thomas S; Munster PN
    Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
    Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
    Margueron R; Duong V; Castet A; Cavaillès V
    Biochem Pharmacol; 2004 Sep; 68(6):1239-46. PubMed ID: 15313422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
    Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
    Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid receptors and their role in the biology and control of breast cancer growth.
    Cordera F; Jordan VC
    Semin Oncol; 2006 Dec; 33(6):631-41. PubMed ID: 17145341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
    Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
    Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane-initiated steroid signaling action of estrogen and breast cancer.
    Song RX
    Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors: clinical update and mechanism-based potential.
    Glaser KB
    Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.